

of direction provided, (g) existence of working examples, and (g) quantity of experimentation necessary.

In the present case, the breadth of claims is narrow and the nature of the invention is simple, being drawn essentially to peptides comprising SEQ ID NO:23 (human PGP-2ac). The state of the prior art is relatively mature and complete regarding making recombinant polypeptides and performing receptor assays (these are routinely practiced techniques in most modern molecular cell biological laboratories) and the level of skill in the art is high, being at the Masters or Ph.D. level. The amount of direction provided in the specification is high, such that GFR α -RET activation assays are completely described and exemplified in the instant specification and the claimed polypeptides are completely described according to the written description guidelines (*i.e.*, as definite amino acid sequence identifiers). Evidence supporting the scientific theory that the GDNF F2a and F2c regions are necessary for GFR α 1-RET activation and working examples of a persephin growth factor substituted with a GDNF "F2a" sequence (AFDDD) and a GDNF "F2c" sequence (YHILRKH) having GFR α 1-RET specificity are provided in the specification (see Example 2 of specification at pages 32 and 33).

Finally, given the "considerable direction and guidance" in the specification (*i.e.*, the RET activation assays are spelled out in sufficient detail to allow the experiment to be repeated with a polypeptide of SEQ ID NO:23 or 26), the "high level of skill in the art" and a working example of a persephin substituted with GDNF "F2a" sequence (AFDDD) and a GDNF "F2c" sequence (YHILRKH), the quantity of experimentation that may be required to demonstrate specific GFR α 1-RET activation activity of SEQ ID NO:23 or 26 is very low and thus not undue or unreasonable. The level of experimentation is reasonable, "since [at least] one embodiment and the method to determine [activity] was set forth in the specification, the specification [is] enabling." See *United States v. Telectronics, Inc.*, 857 F.2d 778, 8 USPQ2d 1217 (Fed. Cir. 1988), *cert. Denied*, 490 U.S. 1046 (1989). Also, the level of experimentation is reasonable since the method of testing the two well described polypeptides of SEQ ID NO:23 and 26 is well described and demonstrated in a working example in the specification. It is a simple matter for the skilled artisan to test poly peptides of SEQ ID NO:23 or 26 as operable GFR α 1-RET

Serial No. 09/473,551

agonists. Importantly, no modifications to the polypeptide sequences or to the method of testing GFR α 1-RET activation are required, hence the level of experimentation is not unreasonable (see MPEP Section 2164.06(a)).

The crux of the Examiner's rejection is that one skilled in the art would not believe that a polypeptide comprising a human persephin that is substituted with the GDNF "F2a" sequence –AFDDD- and the GDNF "F2c" sequence –YHILRKH- would have specific GFR α 1-RET activation activity, in view of a working example of a murine persephin that is substituted with the GDNF "F2a" sequence –AFDDD- and the GDNF "F2c" sequence –YHILRKH- having specific GFR α 1-RET activation activity. Applicants assert that one skilled in the art, who in this case would be a Ph.D. or Masters level molecular cell biologist, would reasonably expect such a substituted human persephin (e.g., a polypeptide of SEQ ID NO:23 or 26) to have specific GFR α 1-RET activation activity for the following reasons: (a) "Wild-type" human and mouse persephin are known in the art to have the same receptor specificity (activation of GFR α 4-RET and not GFR α 1-RET; see reference AW). (b) Example 2 of the instant specification establishes the scientific basis for the necessity of the GDNF "F2a" sequence –AFDDD- and the GDNF "F2c" sequence –YHILRKH- for activation of GFR α 1-RET. (c) A human PGP-2ac and a mouse PGP-2ac are 85% identical and 94% similar to one another (see Exhibit C).

Furthermore, the Examiner's rejection of the claims, which essentially revolves around the alleged lack of a working example of human PGP-2ac having GFR α 1-RET specificity, is improper since "lack of working examples or lack of evidence that the claimed invention works as described should never be the sole reason for rejecting the claimed invention on the grounds of lack of enablement." (See MPEP Section 2164.02.)

In view of the amendments and arguments presented, Applicants believe that the claims are enabled by the specification-as-filed and therefore patentable. Applicants

Serial No. 09/473,551


respectfully request that the rejection of the claims under 35 U.S.C. § 112, first paragraph be withdrawn and the claims allowed to issue. If there are any outstanding issues that need to be resolved, the Examiner is invited to call the undersigned agent.

Respectfully submitted,



Joseph E. Zahner, Ph.D.
Reg. US PTO - 48224
Thompson Coburn LLP
One US Bank Plaza
St. Louis, Missouri 63101
Telephone: 314-552-6354
Fax: 314-552-7354

Serial No. 09/473,551



MARKED-UP COPY OF AMENDED CLAIMS

COPY OF PAPER
ORIGINALLY FILED
RECEIVED
JUN 14 2002
TECH CENTER 1600/2306

1. (Twice amended) A polypeptide which activates GFR α 1-RET but does not substantially activate GFR α 2-RET or GFR α 3-RET, wherein

(a) said polypeptide comprises a persephin as set forth in SEQ ID NO:1, [SEQ ID NO:2 or SEQ ID NO:3,] and further comprises substitutions in region F2a and substitutions in region F2c,

(b) the substitutions in region F2a comprise from one to eight amino acids that are [either] identical to region F2a of a GDNF family ligand, [or contain conservative amino acid substitutions of region F2a of a GDNF family ligand,]

(c) the substitutions in region F2c comprise from one to eight amino acids that are [either] identical to region F2c of a GDNF family ligand, [or contain conservative amino acid substitutions of region F2a of a GDNF family ligand,]

(d) the GDNF family ligand is a peptide [selected from the list consisting] of SEQ ID NO:4[, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10].

7. (Amended) The polypeptide of claim 1 [6], comprising SEQ ID NO:23[, SEQ ID NO:24 or SEQ ID NO:25].

8. (Amended) The polypeptide of claim 1[6], consisting of SEQ ID NO:26[, SEQ ID NO:27 or SEQ ID NO:28].



RECEIVED
JUN 14 2002
TECH CENTER 1600/2900

EXHIBIT C

CLUSTAL W MULTIPLE SEQUENCE ALIGNMENT OF RODENT PGP-F2ac HUMAN PGP-F2ac

SEQ ID NO:12 CRLWSLTLPVAELGLGYASEEKVIFRYCAGSCPOEARTQHSLVRLARLRGRGRAHGRPCCQ
SEQ ID NO:23 CQLWSLTLSVAELGLGYASEEKVIFRYCAGSCPRGARTQHGLALARLQGQGRAHGGPCCR
*.*****.*****.*****.*****.*****.*****.*****.*****.

SEQ ID NO:12 PTAFDDDDVTFLDDQHYYHILRKHSAAACGC
SEQ ID NO:23 PTAFDDDDVAFLDDRHRYYHILRKHSAAACGC
*****.*****.*****.*****.*****.*****.*****.*****.

85
90 similarity

CLUSTAL W(1.4) MULTIPLE SEQUENCE ALIGNMENTS

SEQUENCE FORMAT IS PEARSON

SEQUENCE 1: SEQ ID NO:12 = RODENT PGP-F2ac

90 AA

SEQUENCE 2: SEQ ID NO:23 = HUMAN PGP-F2ac

90 AA

START OF PAIRWISE ALIGNMENTS

ALIGNING...

SEQUENCES (1:2) ALIGNED. SCORE: 85

START OF MULTIPLE ALIGNMENT

THERE ARE 1 GROUPS

ALIGNING...

GROUP 1: SEQUENCES: 2 SCORE:1190

COPY OF PAPERS
ORIGINALLY FILED

CONSENSUS LENGTH = 90

CLUSTAL-ALIGNMENT FILE CREATED [INTERNET.ALN]